{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:19:47Z","timestamp":1768879187201,"version":"3.49.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2403,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Prophylactic therapy is generally used to prevent reactivated hepatitis B after transplantation of an antibody to hepatitis B core antigen (anti-HBc)\u2013positive liver. To gain insight into current practice, a questionnaire was e-mailed to 89 liver transplant physicians in the United States, Europe, and Asia\/Australia and 4 hepatitis B experts. Addressees were asked if they prefer lamivudine or other nucleoside analogs and whether these drugs are used indefinitely. They were also questioned about the use of hepatitis B immune globulin (HBIg), the preferred duration of its administration, and whether treatment strategies differ according to the knowledge of the serologic status of the recipient. Responses were obtained from 78 physicians. All transplant physicians reported the use of nucleoside analog therapy, and 65% prefer lamivudine (58% versus 81% for US and non-US physicians, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.05). Sixty-one percent use HBIg (38% always, 23% sometimes). HBIg was used more frequently in the United States than other parts of the world (69% versus 46%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.03). Eighty-one percent of transplant physicians use nucleoside analog therapy for an indefinite period, but the duration of HBIg treatment varies widely. Although some centers omit nucleoside analog or HBIg therapy in antibody to hepatitis B surface antigen\u2013positive recipients, 90% will not omit these agents if the recipient is positive for anti-HBc alone. In conclusion, nucleoside analog therapy is nearly always used for anti-HBc\u2013positive livers, and most transplant physicians treat for an indefinite period. Lamivudine continues to be preferred as first-line therapy. Many programs also use HBIg, but there is wide variation in the way this is administered. Further study is needed to determine the most cost-beneficial regimen.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.21675","type":"journal-article","created":{"date-parts":[[2009,1,28]],"date-time":"2009-01-28T18:45:29Z","timestamp":1233168329000},"page":"223-232","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":62,"title":["Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen\u2013positive liver donation: A survey of North American, European, and Asian-Pacific transplant programs"],"prefix":"10.1097","volume":"15","author":[{"given":"Robert","family":"Perrillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-14-20250330","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00007890-199501270-00014","article-title":"The risk of transmission of hepatitis B from HBsAg (), HBcAb (), HBIgM () organ donors.","volume":"59","author":"Wachs","year":"1995","journal-title":"Transplantation"},{"key":"R2-14-20250330","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1053\/gast.1997.v113.pm9352871","article-title":"Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen.","volume":"113","author":"Dickson","year":"1997","journal-title":"Gastroenterology"},{"key":"R3-14-20250330","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0168-8278(97)80416-3","article-title":"De novo and apparent de novo hepatitis B virus infection after liver transplantation.","volume":"26","author":"Roche","year":"1997","journal-title":"J Hepatol"},{"key":"R4-14-20250330","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1097\/00007890-199712150-00013","article-title":"Infectivity of hepatic allografts with antibodies to hepatitis B virus.","volume":"15","author":"Dodson","year":"1997","journal-title":"Transplantation"},{"key":"R5-14-20250330","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/00007890-199802270-00007","article-title":"Transmission of hepatitis B virus from hepatitis B core antibodypositive donors in living related liver transplants.","volume":"65","author":"Uemoto","year":"1998","journal-title":"Transplantation"},{"key":"R6-14-20250330","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1053\/jlts.2003.50157","article-title":"Use of hepatitis B core antibodypositive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States.","volume":"9","author":"Burton","year":"2003","journal-title":"Liver Transpl"},{"issue":"suppl 2","key":"R7-14-20250330","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2008.01.011","article-title":"Hepatitis B: reflections on the current approach to antiviral therapy.","volume":"48","author":"Zoulim","year":"2008","journal-title":"J Hepatol"},{"key":"R9-14-20250330","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/1096-9071(200012)62:4<450::AID-JMV9>3.0.CO;2-Y","article-title":"Serological pattern antiHBc alone: report on a workshop.","volume":"62","author":"Grob","year":"2000","journal-title":"J Med Virol"},{"key":"R10-14-20250330","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/lt.500030202","article-title":"The clinical course of transplantationassociated de novo hepatitis B infection in the liver transplant recipient.","volume":"3","author":"Douglas","year":"1997","journal-title":"Liver Transpl Surg"},{"key":"R11-14-20250330","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/jlts.2001.23911","article-title":"Transmission of hepatitis B infection from hepatitis B core antibodypositive liver allografts is prevented by lamivudine therapy.","volume":"6","author":"Yu","year":"2001","journal-title":"Liver Transpl"},{"key":"R12-14-20250330","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1034\/j.1399-0012.2002.01133.x","article-title":"Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors.","volume":"16","author":"Chen","year":"2002","journal-title":"Clin Transplant"},{"key":"R13-14-20250330","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/01.TP.0000065283.98275.FE","article-title":"Use of liver grafts from donors positive for antihepatitis Bcore antibody (antiHBc) in the era of prophylaxis with hepatitisB immunoglobulin and lamivudine.","volume":"75","author":"Nery","year":"2003","journal-title":"Transplantation"},{"key":"R14-14-20250330","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1399-0012.2006.00495.x","article-title":"Longterm lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surfaceantigen negative liver transplant recipients from hepatitis B core antibodypositive donors.","volume":"20","author":"Prakoso","year":"2006","journal-title":"Clin Transplant"},{"key":"R15-14-20250330","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1016\/j.transproceed.2005.07.049","article-title":"Use of hepatitis B core antibodypositive liver allograft in hepatitis C viruspositive and negative recipients with use of short course of hepatitis B immunoglobulin and lamivudine.","volume":"37","author":"Jain","year":"2005","journal-title":"Transplant Proc"},{"key":"R16-14-20250330","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1600-6143.2006.01313.x","article-title":"Case report of lamivudineresistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor.","volume":"6","author":"Yen","year":"2006","journal-title":"Am J Transplant"},{"key":"R17-14-20250330","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jmv.1890350112","article-title":"Hepatitis B virus DNA in sera of virus carriers positive exclusively for antibodies to the hepatitis B core antigen.","volume":"35","author":"Luo","year":"1991","journal-title":"J Med Virol"},{"key":"R18-14-20250330","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1046\/j.1537-2995.2001.41091093.x","article-title":"Frequent presence of HBV in the sera of HBsAgnegative, antiHBcpositive blood donors.","volume":"41","author":"Yotsuyanagi","year":"2001","journal-title":"Transfusion"},{"key":"R19-14-20250330","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1386-6532(02)00171-3","article-title":"The significance of antiHBc only in the clinical virology laboratory.","volume":"27","author":"Alhababi","year":"2003","journal-title":"J Clin Virol"},{"key":"R20-14-20250330","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1046\/j.1537-2995.1993.33393174446.x","article-title":"Absence of hepatitis B virus DNA detected by polymerase chain reaction in blood donors who are hepatitis B surface antigen negative and antibody to hepatitis B core antigen positive from a United States population with a low prevalence of hepatitis B serologic markers.","volume":"33","author":"Douglass","year":"1993","journal-title":"Transfusion"},{"key":"R21-14-20250330","doi-asserted-by":"crossref","first-page":"8882","DOI":"10.1128\/JVI.77.16.8882-8892.2003","article-title":"Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions.","volume":"77","author":"Schilling","year":"2003","journal-title":"J Virol"},{"key":"R23-14-20250330","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1001\/jama.1983.03340180035021","article-title":"Prevaccination screening of medical and dental students. Should low levels of antibody to hepatitis B surface antigen preclude vaccination?","volume":"250","author":"Perrillo","year":"1983","journal-title":"JAMA"},{"key":"R24-14-20250330","doi-asserted-by":"crossref","first-page":"12153","DOI":"10.1016\/j.hs.2003.09.013","article-title":"Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure.","volume":"9","author":"Abdelmalek","year":"2003","journal-title":"Liver Transpl"},{"key":"R25-14-20250330","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/lt.20093","article-title":"Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance.","volume":"10","author":"Ghisetti","year":"2004","journal-title":"Liver Transpl"},{"key":"R26-14-20250330","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/lt.21284","article-title":"Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C.","volume":"14","author":"Shetty","year":"2008","journal-title":"Liver Transpl"},{"key":"R27-14-20250330","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0002-9629(15)40643-3","article-title":"Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation.","volume":"318","author":"Horlander","year":"1999","journal-title":"Am J Med Sci"},{"key":"R28-14-20250330","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1034\/j.1399-0012.2003.00044.x","article-title":"Costeffective and safe ambulatory longterm immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation.","volume":"17","author":"Faust","year":"2003","journal-title":"Clin Transplant"},{"key":"R29-14-20250330","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1053\/j.gastro.2007.01.005","article-title":"Lamivudine plus lowdose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.","volume":"132","author":"Gane","year":"2007","journal-title":"Gastroenterology"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.21675","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-200902000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:04:36Z","timestamp":1743379476000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-200902000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.21675","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}